8. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)
Stock Upside: 58.52%
Market Capitalization: $6.13 billion
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) takes the eighth spot on this list of the most promising healthcare stocks according to Wall Street analysts, and unlike broad healthcare giants, this company is built around a more specialized but emotionally powerful treatment area: rare genetic diseases of obesity. Trading at $96.79, with the stock up 1.00%, Rhythm Pharmaceuticals, Inc. (NASDAQ) has a market capitalization of $6.13 billion, a stock upside of 58.52%, and 47 hedge fund holders as of Q1 2026. For investors searching for rare disease stocks, biotech stocks with upside, obesity treatment stocks, genetic disease stocks, and healthcare stocks to buy now, Rhythm offers a story that sits at the intersection of endocrinology, obesity medicine, and rare genetic disorders.
On June 13, Rhythm Pharmaceuticals, Inc. (NASDAQ) shared preliminary results from its ongoing Phase 2 trial of setmelanotide for Prader-Willi syndrome, or PWS, during the Endocrine Society’s Annual Meeting in Chicago. That is a meaningful venue for this type of data because endocrinology sits at the center of hormones, metabolism, appetite regulation, and obesity science. In the trial, Rhythm said setmelanotide showed meaningful improvements in weight, body composition, hunger, and behavioral outcomes. For a typical obesity drug, weight-loss data may be enough to attract attention. But for Prader-Willi syndrome, the story is more complicated because the condition is not simply about weight. It is about a severe genetic disorder that can create relentless hunger, behavioral challenges, and long-term health risks beginning early in life.
Prader-Willi syndrome is rare, but for families affected by it, the condition can be overwhelming. It often causes a near-constant sense of hunger that begins in childhood, along with severe obesity and behavioral or emotional difficulties. This hunger, known clinically as hyperphagia, is not the same as ordinary appetite. It can be intense, persistent, and extremely difficult to manage. That is why treatments targeting PWS are watched closely by physicians, families, and biotech investors. There are still very few therapies that can meaningfully address the underlying features of the condition, so any drug that improves hunger and weight-related outcomes can quickly become important.
According to Rhythm’s preliminary data, patients saw average BMI reductions of just over 3% at the six-month mark. The reductions were seen across both adult and pediatric patients, which is important because PWS affects individuals across age groups. The company also said setmelanotide produced meaningful improvement in excessive hunger, with 8 out of 10 patients who entered the trial with moderate to severe hyperphagia showing significant improvement in hunger scores. For investors looking at promising biotech stocks, these details matter because they suggest the drug may be doing more than producing modest weight movement. It may be affecting one of the core symptoms that makes PWS so difficult to treat.
Rhythm also reported that the safety profile of setmelanotide in this trial was consistent with what had already been established in prior studies. That matters because rare disease drug development is not only about efficacy. Safety becomes especially important when treating children, long-term metabolic disorders, or conditions that may require ongoing therapy. The company said the results give it confidence to move into a Phase 3 trial for PWS, which would be a larger and more rigorous study. For biotech investors, that transition from Phase 2 to Phase 3 is a major step because it moves a program closer to the kind of evidence regulators typically need for approval consideration.
Rhythm Pharmaceuticals, Inc. (NASDAQ) is already a commercial-stage biopharmaceutical company focused on therapies for rare genetic diseases of obesity. That focus gives it a differentiated place in the healthcare sector. The obesity treatment market has become one of the hottest areas in healthcare, especially because of the rise of GLP-1 drugs, but Rhythm is not simply competing in the mainstream weight-loss category. Its story is more targeted. It is focused on rare genetic obesity conditions where biology, appetite signaling, and unmet need create a very different treatment landscape.
For investors searching for the best healthcare stocks, biotech stocks with high upside, rare disease obesity stocks, and Wall Street analyst healthcare stock picks, Rhythm stands out because it has both a commercial rare-disease identity and a pipeline catalyst tied to Prader-Willi syndrome. With a 58.52% stock upside estimate and a $6.13 billion market capitalization, Rhythm is not a tiny speculative biotech, but it still carries the kind of clinical-catalyst profile that can attract attention when data improves. If the Phase 3 path confirms the early signals, Rhythm could remain one of the more closely watched rare disease healthcare stocks on Wall Street.
Click next to see the following stock...
